Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Minodronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 9/20 | 1.00 |
| ▸ | GGPS1 | O95749 | 3/20 | 1.00 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minodronic Acid SCHEMBL8661646 | 0.99 | FDPS (0.97) | FDPSGGPS1GPR84BTN3A1PDE3A | |
| Minodronic Acid SCHEMBL6009958 | 0.99 | FDPS (0.97) | FDPSGGPS1GPR84BTN3A1PDE3A | |
| Minodronic Acid SCHEMBL8661643 | 0.92 | FDPS (0.85) | FDPSGGPS1GPR84BTN3A1PDE3A | |
| Minodronic Acid SCHEMBL8664061 | 0.91 | FDPS (0.83) | FDPSGGPS1GPR84BTN3A1PDE3A | |
| Minodronic Acid SCHEMBL8659642 | 0.91 | FDPS (0.83) | FDPSGGPS1GPR84BTN3A1PDE3A | |
| SCHEMBL12309035 | 0.84 | FDPS (0.73) | FDPSGGPS1GPR84NPSR1DRD4 | |
| (2-Hydroxy-3-Imidazo[1,2-A]Pyridin-3-Yl-2-Phosphonopropionic Acid (Enantionmers) SCHEMBL7858749 | 0.84 | FDPS (0.72) | FDPSGGPS1GPR84NPSR1DRD4 | |
| SCHEMBL17519343 | 0.84 | FDPS (0.72) | FDPSGGPS1GPR84NPSR1DRD4 | |
| SCHEMBL28033480 | 0.84 | FDPS (0.72) | FDPSGGPS1GPR84NPSR1DRD4 | |
| SCHEMBL17519328 | 0.82 | GGPS1 (0.69) | FDPSGGPS1GPR84NPSR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3860 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| US-12600945-B2 | Human Vγ9Vδ2T cell proliferation culture method and culture medium | Guangdong GD Kongming Biotech LLC (CN) | 2026-04-14 | — | — | US | claimed |
| EP-4703409-A1 | LIGHT-RESPONSIVE CELL DESIGNER MOLECULE | The University of Osaka (JP) | 2026-03-04 | — | — | EP | claimed |
| US-12529035-B1 | Method for producing induced pluripotent stem cells | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2026-01-20 | — | — | US | claimed |
| WO-2025261951-A1 | COMBINATION THERAPY WITH AN ANTI-CA19-9 ANTIBODY AND FOLFIRINOX IN THE TREATMENT OF CANCER | BioNTech SE (DE) | 2025-12-26 | — | — | WO | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| EP-3904506-B1 | HUMAN V GAMMA 9V DELTA 2T CELL PROLIFERATION CULTURE METHOD AND CULTURE MEDIUM | Guangdong GD Kongming Biotech LLC (CN) | 2025-07-16 | — | — | EP | claimed |
| CN-109106600-B | Glue solution conveying system and preparation method | 江苏恒瑞医药股份有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119936247-A | Minodronate tablet is a method for analyzing the dissolution rate of (2) | 安徽博诺美科生物医药有限公司 | 2025-05-06 | — | — | CN | claimed |
| US-12285489-B2 | Bone targeted antimicrobial oxazolidinone related compounds, formulations thereof, and uses thereof | EBETINO FRANK HALLOCK (US) | 2025-04-29 | — | — | US | claimed |
| WO-2000071104-A2 | USE OF BISPHOSPHONIC ACIDS FOR TREATING ANGIOGENESIS | NOVARTIS AG (CH) | 2000-11-30 | — | — | WO | claimed |
| EP-0998934-A1 | REMEDIES FOR INTRAMEDULLARY DISEASES | TORAY INDUSTRIES, INC. (JP) | 2000-05-10 | — | — | EP | claimed |
| EP-0854724-A1 | METHOD OF TREATING THE NAVICULAR DISEASE IN HORSES | Novartis AG (CH) | 1998-07-29 | — | — | EP | claimed |
| WO-1997012619-A1 | METHOD OF TREATING THE NAVICULAR DISEASE IN HORSES | NOVARTIS AG (CH) | 1997-04-10 | — | — | WO | claimed |
| EP-0758241-A1 | USE OF CERTAIN METHANEBISPHOSPHONIC ACID DERIVATIVES TO PREVENT PROSTHESIS LOOSENING AND PROSTHESIS MIGRATION | Novartis AG (CH) | 1997-02-19 | — | — | EP | claimed |
| WO-1995030421-A1 | USE OF CERTAIN METHANEBISPHOSPHONIC ACID DERIVATIVES TO PREVENT PROSTHESIS LOOSENING AND PROSTHESIS MIGRATION | CIBA-GEIGY AG (CH) | 1995-11-16 | — | — | WO | claimed |
| EP-0354806-B1 | Heterocyclic bisphosphonic acid derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1995-11-02 | — | — | EP | claimed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | claimed |
| US-4990503-A | A bone resorption inhibitor | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-02-05 | — | — | US | claimed |
| EP-0354806-A2 | Heterocyclic bisphosphonic acid derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-02-14 | — | — | EP | claimed |